<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543801</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2022</org_study_id>
    <nct_id>NCT02543801</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty</brief_title>
  <official_title>A Prospective, Randomized Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kootenai Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kootenai Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two routinely used drug combinations for periarticular injection
      following total hip arthroplasty for pain control. One group will receive liposomal
      bupivacaine, bupivacaine, clonidine, epinephrine and ketorolac. The other group will receive
      ropivacaine, clonidine, epinephrine and ketorolac.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A key component of the multimodal approach to pain management is the intra-operative surgical
      site injection of a local anesthetic or drug cocktail. There are many formulations used for
      this purpose. A formulation documented in the literature was implemented by this institution
      which has dropped the average length of stay dramatically. Concern over the limited half-life
      of the administered anesthetic and the continued need for opioid administration has led to a
      search for better drug formulations and administration vehicles. Recently, the FDA approval
      of an extended release bupivacaine called liposomal bupivacaine was thought to extend the
      effective half-life of the anesthetic agent and thereby prolong post-operative anesthesia.
      Use of liposomal bupivacaine in total joint surgery was almost universally adopted after its
      recent approval and has been an integral part of the &quot;same day total joint&quot; movement.

      Studies have suggested improvement in pain control and shortened hospitalizations with the
      use of liposomal bupivacaine. Other studies have raised questions about the effectiveness of
      this agent. Recently a randomized double blind study was performed with total knees which
      demonstrated no improvement in pain management with the addition of liposomal bupivacaine to
      the multimodal pain management protocol. This study has not been performed in the hip
      arthroplasty population.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Hospitalization duration, an expected average of 48 hours</time_frame>
    <description>Self-reported pain score 1-10 (1=no pain - 10=worst possible pain experienced)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic consumption</measure>
    <time_frame>For the hospitalization duration,an expected average of 48 hours</time_frame>
    <description>Total amount of narcotics administered as calculated in oral morphine equivalent dose for duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospitalization duration, an expected average of 48 hours</time_frame>
    <description>Measured in hours from start of surgery to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine Clonidine Epinephrine Ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Periarticular injection</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Included as an element of the Liposomal bupivacaine intervention periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Duraclon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hip Arthritis (osteoarthritis, post traumatic, inflammatory, and avascular necrosis)

        Exclusion Criteria:

          -  Current use of opioid drugs

          -  Revision surgery

          -  Surgical complication (femoral fracture with implant insertion)

          -  Inability to provide Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Bowen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kootenai Health</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

